Ikeda Keiichi K

Show results for

Metabolomics (3)
Models (2)

Organisms

cellular organisms (2)

Repository

MetaboLights (3)
BioModels (2)

Technology Type

Mass spectrometry (3)

Instrument Platform

Capillary electrophoresis MS - negative (3)
Capillary electrophoresis MS - positive (3)

Publication Date

2023 (3)
2024 (2)

UNIPROT ID/AC

P04075 (2)
P09467 (2)
P17858 (2)
P06213 (1)
P23443 (1)
P31749 (1)
P42345 (1)

CHEBI ID

CHEBI:10049 (3)
CHEBI:10072 (3)
CHEBI:1026 (3)
CHEBI:1148 (3)
CHEBI:1157 (3)
CHEBI:132546 (3)
CHEBI:132958 (3)
CHEBI:134206 (3)
CHEBI:135063 (3)
CHEBI:139328 (3)
CHEBI:14314 (3)
CHEBI:143269 (3)
CHEBI:14336 (3)
CHEBI:1456 (3)
CHEBI:14973 (3)
CHEBI:15318 (3)
CHEBI:15346 (3)
CHEBI:15351 (3)
CHEBI:15354 (3)
CHEBI:15355 (3)
CHEBI:15946 (2)
CHEBI:16905 (2)
CHEBI:18021 (2)
CHEBI:28602 (2)
CHEBI:30769 (2)
CHEBI:30887 (2)
CHEBI:30915 (2)
CHEBI:57579 (2)
CHEBI:6650 (2)
CHEBI:36080 (1)

Metabolite Name

(Methylthio)acetate (2)
1-Aminoethylphosphonate (2)
10-Hydroxydecanoate (2)
2',3'-cCMP (2)
2,3-DPG (2,3-Disphospho-D-glycerate) (2)
2,3-Pyridinedicarboxylate (2)
2,4-Dihydroxypyrimidine-5-carboxylate (2)
2,5-Dihydroxybenzoate (2)
2-Amino-3-phosphonopropionate (2)
2-Aminoethylphosphonate (2)
2-Deoxyglucose 6-phosphate (2)
2-Deoxyribose 1-phosphate (2)
2-Furoate (2)
2-Hydroxy-4-methylpentanoate (2)
2-Hydroxybutyrate (2)
2-Hydroxyglutarate (2)
2-Hydroxyisobutyrate (2)
2-Hydroxyoctanoate (2)
2-Hydroxypentanoate (2)
2-Hydroxyphenylacetate (2)
2-Isopropylmalate (2)
2-Oxoadipate (2)
2-Oxobutyrate (2)
2-Oxoglutarate (2)
2-Oxoisopentanoate (2)
2-Oxooctanoate (2)
2-Quinolinecarboxylate (2)
2-Thiopheneacetate (2)
2PG (D-Glycerate 2-phosphate) (2)
3',5'-Cyclic dAMP (2)

IsPrivate

False (2)

Modelling Approach

Ordinary differential equation model (2)

Previous page
1 / 1
You're on page 1
Next page

Sort by:

Relevance

Page size

Yugi2014 - Insulin induced signalling (PFKL phosphorylation) - model 1

Yugi2014 - Insulin induced signalling (PFKL phosphorylation) - model 1 Insulin induces phosphorylation and activation of liver-type phosphofructokinase 1, which thereby controls a key reaction in glycolysis. This mechanism is revealed using the mathematical model. In this model, the PFKL ph...

2024-09-02 | BIOMD0000000540 | BioModels

Yugi2014 - Insulin induced signalling (PFKL phosphorylation) - model 2

Yugi2014 - Insulin induced signalling (PFKL phosphorylation) - model 2 Insulin induces phosphorylation and activation of liver-type phosphofructokinase 1, which thereby controls a key reaction in glycolysis. This mechanism is revealed using the mathematical model. In this model, the PFKL ph...

2024-09-02 | BIOMD0000000541 | BioModels

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Cell NAMPTi treatment)

NAMPT plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi...

2023-10-10 | MTBLS7251 | MetaboLights

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Mouse NAMPT targeted therapy)

2023-10-10 | MTBLS7252 | MetaboLights

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Mouse NAD targeted time-course)

2023-10-10 | MTBLS7253 | MetaboLights